Recombinant Factor VIII Fc Inhibits B Cell Activation via Engagement of the FcγRIIB Receptor

The development of neutralizing antibodies (inhibitors) against factor VIII (FVIII) is a major complication of hemophilia A treatment. The sole clinical therapy to restore FVIII tolerance in patients with inhibitors remains immune tolerance induction (ITI) which is expensive, difficult to administer...

Descripción completa

Detalles Bibliográficos
Autores principales: Georgescu, Maria T., Moorehead, Paul C., Liu, Tongyao, Dumont, Jennifer, Scott, David W., Hough, Christine, Lillicrap, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7025534/
https://www.ncbi.nlm.nih.gov/pubmed/32117285
http://dx.doi.org/10.3389/fimmu.2020.00138

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7025534/
https://www.ncbi.nlm.nih.gov/pubmed/32117285
http://dx.doi.org/10.3389/fimmu.2020.00138

Ejemplares similares